P206 - Which patient population profits best from a high dose, once daily treatment with 3.0g mesalazine for maintaining clinical remission in ulcerative colitis? A subgroup analysis of a double-blind, double-dummy, randomised, controlled, dose-ranging study

W. Kruis; L. Jonaitis; L. Kupcinskas; J. Pokrotnieks; G. Acute; T.L. Mikhailova; M. Horynski; M. Batovsky; Y.S. Lozinskii; I. Racz; K. Kull; A. Vcev; M. Faszczyk; R. Greinwald; R. Mueller

作者W. Kruis; L. Jonaitis; L. Kupcinskas; J. Pokrotnieks; G. Acute; T.L. Mikhailova; M. Horynski; M. Batovsky; Y.S. Lozinskii; I. Racz; K. Kull; A. Vcev; M. Faszczyk; R. Greinwald; R. Mueller
卷第3卷
期第1期
文件大小50.60KB
发表时间2009
DOI10.1016/s1873-9946(09)60233-6

发现好书期刊，享受阅读乐趣

P206 - Which patient population profits best from a high dose, once daily treatment with 3.0g mesalazine for maintaining clinical remission in ulcerative colitis? A subgroup analysis of a double-blind, double-dummy, randomised, controlled, dose-ranging study